BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35195909)

  • 1. The prognostic significance of further genotyping H3G34 diffuse hemispheric gliomas.
    Vuong HG; Le HT; Dunn IF
    Cancer; 2022 May; 128(10):1907-1912. PubMed ID: 35195909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High frequency of PDGFRA and MUC family gene mutations in diffuse hemispheric glioma, H3 G34-mutant: a glimmer of hope?
    Hu W; Duan H; Zhong S; Zeng J; Mou Y
    J Transl Med; 2022 Feb; 20(1):64. PubMed ID: 35109850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults.
    Picart T; Barritault M; Poncet D; Berner LP; Izquierdo C; Tabouret E; Figarella-Branger D; Idbaïh A; Bielle F; Bourg V; Vandenbos FB; Moyal EC; Uro-Coste E; Guyotat J; Honnorat J; Gabut M; Meyronet D; Ducray F
    Neurooncol Adv; 2021; 3(1):vdab061. PubMed ID: 34056608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4.
    Williams EA; Brastianos PK; Wakimoto H; Zolal A; Filbin MG; Cahill DP; Santagata S; Juratli TA
    Acta Neuropathol; 2023 Sep; 146(3):515-525. PubMed ID: 37524847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Midline invasion predicts poor prognosis in diffuse hemispheric glioma, H3 G34-mutant: an individual participant data review.
    Kegoya Y; Otani Y; Inoue Y; Mizuta R; Higaki F; Washio K; Koizumi S; Kurozumi K; Ishida J; Fujii K; Yamamoto N; Tanaka Y; Date I
    J Neurooncol; 2024 Mar; 167(1):201-210. PubMed ID: 38427132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI characteristics of H3 G34-mutant diffuse hemispheric gliomas and possible differentiation from IDH-wild-type glioblastomas in adolescents and young adults.
    Shao H; Gong J; Su X; Chen N; Li S; Yang X; Zhang S; Huang Z; Hu W; Gong Q; Liu Y; Yue Q
    J Neurosurg Pediatr; 2024 Mar; 33(3):236-244. PubMed ID: 38157540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. H3G34-mutant diffuse hemispheric glioma with osseous metastases: a case report and literature review.
    Yu N; Lee HS; Raslan OA; Jin LW; Aboud O
    CNS Oncol; 2023 Jun; 12(2):CNS95. PubMed ID: 36919796
    [No Abstract]   [Full Text] [Related]  

  • 8. Neuroimaging features of diffuse hemispheric glioma, H3 G34-mutant: A case series and systematic review.
    Kurokawa R; Baba A; Kurokawa M; Pinarbasi ES; Makise N; Ota Y; Kim J; Srinivasan A; Moritani T
    J Neuroimaging; 2022 Jan; 32(1):17-27. PubMed ID: 34632671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation Between Immunohistochemistry and Sequencing in H3G34-Mutant Gliomas.
    Gianno F; Antonelli M; Di Dio T; Minasi S; Donofrio V; Buccoliero AM; Gardiman MP; Pollo B; Diomedi Camassei F; Rossi S; Novello M; Giangaspero F; Arcella A; Gessi M; Buttarelli FR
    Am J Surg Pathol; 2021 Feb; 45(2):200-204. PubMed ID: 33428336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. H3K27M-mutant diffuse midline gliomas should be further molecularly stratified: an integrated analysis of 669 patients.
    Vuong HG; Le HT; Ngo TNM; Fung KM; Battiste JD; McNall-Knapp R; Dunn IF
    J Neurooncol; 2021 Dec; 155(3):225-234. PubMed ID: 34796414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. H3G34-Mutant Gliomas-A Review of Molecular Pathogenesis and Therapeutic Options.
    Nguyen AV; Soto JM; Gonzalez SM; Murillo J; Trumble ER; Shan FY; Huang JH
    Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. H3 G34-mutant high-grade gliomas: integrated clinical, imaging and pathological characterisation of a single-centre case series.
    Lavrador JP; Reisz Z; Sibtain N; Rajwani K; Baig Mirza A; Vergani F; Gullan R; Bhangoo R; Ashkan K; Bleil C; Zebian B; Clark B; Laxton R; King A; Bodi I; Al-Saraj S
    Acta Neurochir (Wien); 2023 Jun; 165(6):1615-1633. PubMed ID: 36929449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review of diffuse hemispheric glioma, H3 G34-mutant: Outcomes and associated clinical factors.
    Crowell C; Mata-Mbemba D; Bennett J; Matheson K; Mackley M; Perreault S; Erker C
    Neurooncol Adv; 2022; 4(1):vdac133. PubMed ID: 36105387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer-driving H3G34V/R/D mutations block H3K36 methylation and H3K36me3-MutSα interaction.
    Fang J; Huang Y; Mao G; Yang S; Rennert G; Gu L; Li H; Li GM
    Proc Natl Acad Sci U S A; 2018 Sep; 115(38):9598-9603. PubMed ID: 30181289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
    Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
    Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffusion Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3-K27M Mutation Using Apparent Diffusion Coefficient Histogram Analysis.
    Aboian MS; Tong E; Solomon DA; Kline C; Gautam A; Vardapetyan A; Tamrazi B; Li Y; Jordan CD; Felton E; Weinberg B; Braunstein S; Mueller S; Cha S
    AJNR Am J Neuroradiol; 2019 Nov; 40(11):1804-1810. PubMed ID: 31694820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
    Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
    Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anaplastic pleomorphic xanthoastrocytoma associated with an H3G34 mutation: a case report with review of literature.
    Sasaki S; Tomomasa R; Nobusawa S; Hirato J; Uchiyama T; Boku E; Miyasaka T; Hirose T; Ohbayashi C
    Brain Tumor Pathol; 2019 Oct; 36(4):169-173. PubMed ID: 31350684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.